VBI Vaccines (NASDAQ:VBIV) Reaches New 1-Year High at $3.50

Share on StockTwits

VBI Vaccines Inc (NASDAQ:VBIV) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $3.50 and last traded at $2.99, with a volume of 37890400 shares trading hands. The stock had previously closed at $2.99.

A number of analysts recently issued reports on VBIV shares. BidaskClub upgraded VBI Vaccines from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 18th. Canaccord Genuity reiterated a “buy” rating and issued a $4.00 price target on shares of VBI Vaccines in a report on Friday, March 6th. BMO Capital Markets reiterated a “buy” rating and issued a $4.00 price target on shares of VBI Vaccines in a report on Monday. Zacks Investment Research lowered VBI Vaccines from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 25th. Finally, Oppenheimer upped their target price on VBI Vaccines from $5.00 to $8.00 and gave the stock an “outperform” rating in a report on Tuesday, June 23rd. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $4.10.

The business has a fifty day simple moving average of $2.33 and a two-hundred day simple moving average of $1.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.30 and a quick ratio of 1.28. The company has a market cap of $689.64 million, a PE ratio of -8.86 and a beta of 1.69.

VBI Vaccines (NASDAQ:VBIV) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $0.42 million during the quarter, compared to analyst estimates of $0.83 million. VBI Vaccines had a negative return on equity of 57.79% and a negative net margin of 2,133.79%. On average, equities research analysts predict that VBI Vaccines Inc will post -0.19 EPS for the current year.

In other VBI Vaccines news, major shareholder Life Sciences Maste Perceptive purchased 9,090,909 shares of VBI Vaccines stock in a transaction dated Friday, April 24th. The shares were acquired at an average cost of $1.21 per share, with a total value of $10,999,999.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.00% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of VBI Vaccines by 13.0% during the first quarter. BlackRock Inc. now owns 11,678,848 shares of the biopharmaceutical company’s stock worth $11,095,000 after purchasing an additional 1,341,519 shares in the last quarter. Geode Capital Management LLC increased its position in shares of VBI Vaccines by 67.6% in the 4th quarter. Geode Capital Management LLC now owns 2,447,848 shares of the biopharmaceutical company’s stock valued at $3,378,000 after acquiring an additional 987,072 shares during the period. State Street Corp increased its position in shares of VBI Vaccines by 15.1% in the 1st quarter. State Street Corp now owns 2,362,367 shares of the biopharmaceutical company’s stock valued at $2,244,000 after acquiring an additional 310,001 shares during the period. First Midwest Bank Trust Division increased its position in shares of VBI Vaccines by 42.3% in the 1st quarter. First Midwest Bank Trust Division now owns 2,032,457 shares of the biopharmaceutical company’s stock valued at $1,931,000 after acquiring an additional 604,051 shares during the period. Finally, Nuveen Asset Management LLC increased its position in shares of VBI Vaccines by 53.6% in the 1st quarter. Nuveen Asset Management LLC now owns 639,155 shares of the biopharmaceutical company’s stock valued at $607,000 after acquiring an additional 223,118 shares during the period. 33.88% of the stock is currently owned by institutional investors and hedge funds.

About VBI Vaccines (NASDAQ:VBIV)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Further Reading: What causes a yield curve to invert?

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Piper Sandler Weighs in on Kearny Financial Corp.’s FY2020 Earnings
Piper Sandler Weighs in on Kearny Financial Corp.’s FY2020 Earnings
Spirit AeroSystems  Stock Price Up 17.3%
Spirit AeroSystems Stock Price Up 17.3%
Matthews International  Hits New 12-Month Low at $17.01
Matthews International Hits New 12-Month Low at $17.01
Sino Biopharmaceutical  Reaches New 12-Month High at $1.98
Sino Biopharmaceutical Reaches New 12-Month High at $1.98
TOKYO ELECTRON/ADR  Hits New 52-Week High at $61.97
TOKYO ELECTRON/ADR Hits New 52-Week High at $61.97
Digital Turbine  Hits New 52-Week High at $12.06
Digital Turbine Hits New 52-Week High at $12.06


© 2006-2020 Ticker Report